Case Report

A juvenile case with nonalcoholic steatohepatitis and traditional Korean medicine-based treatment

Chang-Gue Son*

Liver and Immunology Research Center, Oriental Medical College of Daejeon University, Korea

ARTICLE INFO

Article history:
Received 15 December 2017
Revised 16 January 2018
Accepted 18 January 2018

Keywords:
NAFLD
NASH
Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis
Traditional Korean medicine

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) has become the common cause leading to chronic liver diseases recently. Unlike past humankind history, NAFLD is like a new illness especially in developed countries due to decreased number of hepatic virus carriers and increased population with obesity. Among subjects with NAFLD, development of nonalcoholic steatohepatitis (NASH) is a key pathological step which determines the clinical progression. This study reports a case of a boy who has suffered from NASH for 2 years. This study aims to discuss the clinical feature, risk aspect, and treatment strategy of NASH as well as potential of traditional Korean medicine (TKM) therapies.

© 2018 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Hepatic steatosis is a condition of the excessive accumulation of triglyceride fat in hepatocytes, and fatty liver disease refers the any liver disease with hepatic steatosis.\(^1\) Alcohol consumption is a main cause of hepatic steatosis; however, recently many subjects are suffering from nonalcohol-related fatty liver, called as nonalcoholic fatty liver disease (NAFLD). In a recent meta-analysis, the global prevalence of NAFLD is known to rise by approximately 25% in especially developed countries.\(^2\) Along to increase of population with obesity, the incidence and disease burden from NAFLD will continue to increase.\(^3,4\)

NAFLD is now considered as a silent killer by a new epidemic of the Third Millennium.\(^5\) NAFLD is known to show a strong association with diabetes mellitus, cardiovascular disease or cerebrovascular disease as well as high cancer incidence of 1.3 hazard ratio (HR), especially 16.7 HR for hepatocellular carcinoma respectively.\(^6-8\) For Asian population including Korean, NAFLD appears as a medical issue in the past two decades, due to rapid urbanization, sedentary lifestyle, or over nutrition.\(^9\) NAFLD also becomes a common in children and adolescents with prevalence of 7.6% for general population and 34.2% for obese children.\(^10\)

In contrast, the clinical risk of NAFLD is defined by progression into non-alcoholic steatohepatitis (NASH), a pathologic condition characterized by inflammation and damage in

---

* Corresponding author. Liver and Immunology Research Center, Daejeon Oriental Hospital of Daejeon University, 22-5 Daehung-dong, Jung-gu, Daejeon 301-724, Republic of Korea.
E-mail address: ckson@dju.ac.kr
https://doi.org/10.1016/j.imr.2018.01.006
2213-4220/© 2018 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
hepatic tissue. Both NAFLD and NASH have a complex pathology involving the imbalance between lipogenesis and lipolysis, leading to lipotoxicity. In aspect of medicinal herbs composing multi-compounds and pathophysiological features of multi-targets of NAFLD and NASH, herbs-derived remedies are emerging as potential therapeutics recently.

This report aimed to demonstrate a typical case of adolescent patient with NASH, and discuss the clinical feature, risk aspect, and treatment strategy by traditional Korean medicine (TKM)-based therapeutics.

2. Case report

2.1. Characteristics of patient and medical history

A 16-year-old boy visited a Korean medicine hospital with uncomfortable symptom in gastrointestinal function such as mild abdominal pain, diarrhea, as well as frequent fatigue since 12 months ago. He has visited frequently the nurse’s office at school because of abdominal pain after entering high school. Several medical examinations found no abnormality in abdominal X-ray and colonoscopy at a Western hospital, but noticed the moderate fatty liver with the elevated serum level of alanine aminotransferase (ALT) by 100 IU/L. Based on the diagnosis of irritable bowel syndrome (IBS), the irregular medications were given to treat only IBS, but the long-term symptoms became worse. The boy neither drank alcoholic beverages nor smoked cigarettes earlier, but still prefers to eat fast foods and oily snack. His parents decided to receive TKM therapeutics against abdominal pain and hepatic inflammation.

2.2. Diagnosis, treatments, and course of symptom

After visiting the Korean medicine hospital, the patient had been examined using biochemistry, complete blood counts, urinalysis, and ultrasonography. Based on the finding of abnormality in only serum ALT (81 IU/L, normal range 0–40 IU/L) and moderate fatty liver in ultrasonography, he was diagnosed with NASH (Fig. 1A). The patient was a little fatty body (body mass index, BMI 26.0), but has a shape of central obesity as thin four limbs and tummy fat. The genomic analysis using his salivary contents was conducted by a company (Genoplan, Co.), and then the body’s genome showed the vulnerable feature for fat and glucose metabolic problem (Fig. 1B).

The patient complained physical lethargy and less motivation for everything including school life, with sudden and frequent abdominal pain at middle abdominal area. The status of the coat on his tongue was mild pink color, and pulsation was tender. No abnormal tension was in abdominal area. His symptom differentiation was diagnosed as “disharmony between liver and spleen (肝脾不和)”. The patient was administered with an herbal drug, Chunggwanplus (Chunggwanplus, Table 1) twice per day. In addition, Taeumin taeguk acupuncture (helping HT4; 胆 Visitors LU9; 三焦, but reducing LR3; 冲门 for 20 min once a week for 3 months with 0.25 × 30 needles purchased from DongBang Co. Seoul), and indirect moxibustion on umbilical area were given to the patient. In particular, physical exercise and diet management were strongly recommended, and thus he had joined a boxing gym and regularly did the practice three times weekly. He had reduced body weight about 3 kg during 6 months and the general symptoms including abdominal pain as well as blood chemistry (ALT by 41 IU/L) were improved.

3. Discussion

According to the change of medical environments, such as less population of hepatitis B type virus carrier, increase of obese subjects and over calorie diet habit, NAFLD evolved as a serious public health problem in developed countries. NAFLD increases liver-related morbidity and mortality, and also is linked to the extra-hepatic diseases such as metabolic syndrome, type 2 diabetes mellitus, dyslipidemia, hypertension, cardiovascular or cerebrovascular diseases, and even chronic kidney disease. No currently available drug-based therapy

| Table 1 – Composition of Chunggwanplus |
| Weight (g) | Composition (10 mL syrup containing 2 g extract from 13 herbs) |
| 5 g | Artemisia capillaris Herba, Carapax Trionycis, Semen Raphani |
| 3 g | Rhizoma Atractylodis Macrocephalae, Poria, Alismatis Rhizoma, Atractylodis Rhiza, Salviae Miltiorrhizae Radix |
| 2 g | Polyergus, Amomi Fructus, Aurantii Fructus |
| 1 g | Glycyrrhizae Radix, Helianthus Radix |

Fig. 1 – Sonographic finding in liver. The moderate fatty liver and a hemangioma and multiple cysts were found in abdominal nosography (A), and SNP analysis showed the vulnerable feature for fat and glucose metabolism (B).
has been approved yet, and then herbs have been attracted as potential therapeutics against NAFLD because of terms of multi-targets and multi-compounds.\textsuperscript{17}

The present study reports a juvenile case suffering from NASH, a typical condition of hepatic inflammation and damage of NAFLD. In general, obesity is well known as an independent risk factor for NAFLD, which 21.7% increase of BMI is 3.4 odd ratios for development of NAFLD in a middle aged cohort study.\textsuperscript{18} Age is another risk factor for NAFLD, but the present case is young boy and has a little fatty body as BMI 26.0. These facts suggested the presence of any other risk factors including genetic feature in the boy patient. Beside a high-fat diet and inactive lifestyles, the interplay between diet, gut microbiota, and genetic background is believed to be more important in the development and progression of NAFLD.\textsuperscript{19}

In fact, the boy had enjoyed the fast foods and oily snack with low physical activity; furthermore he had the SNP-based genetic feature presenting the low capacity in fat and glucose metabolism.

Regarding the hepatic risk of NAFLD, the development of NASH is a clinical key step determining the progress into hepatic fibrosis, cirrhosis and/or hepatocellular cancer, and then NASH is predicted to become the leading cause of liver transplantation in the USA by 2020.\textsuperscript{20,21} In general, approximately 10% of subjects with NAFLD are known to present the NASH feature, of which 10–25% would progress into cirrhosis.\textsuperscript{22} This case was hepatic inflammation, but not progressed into fibrotic change yet, however his uncontrolled NASH could progress into liver cirrhosis due to the early onset at very young age. Furthermore, recent evidence has suggested that NAFLD may directly promote hepatic carcinogenesis independent of cirrhosis.\textsuperscript{23} The nosography of this patient showed a mass-like regions, but fortunately hemangiomia and multiple cysts were proved via the computed tomography (data not shown). In addition, he might have comorbid of type 2 diabetes mellitus in the future, related to central obesity body shape and genetic analysis in the future. His Sasang constitutional type was judged as Taeumin-type, and then Taeumin-type individual was known to have the highest prevalence in metabolic syndrome and its associated disorders.\textsuperscript{24}

Based on his gastrointestinal symptoms and physical features, the symptom differentiation was diagnosed as “disharmony between liver and spleen (肝脾不和)”. Along with the acupuncture, moxibustion, and herbal prescription (Chungganplus), the boy had been strictly educated to practice the physical exercise and diet control for his NASH treatment. Although no therapeutics to cure the NAFLD or NASH is available in conventional medicine, lifestyle modifications with physical exercise and diet control showed the curative effects.\textsuperscript{25} Weight reductions of >10% can resolve NASH and induce fibrosis improvement, and modest weight loss (>5%) can also produce important benefits on NAFLD management.\textsuperscript{26} In this case, the regular boxing practice and diet control reduced his body weight 3 kg (about 4%, from 75 kg to 72 kg) during 6 months, which might attenuate the lipotoxic reaction in liver. Chungganplus was known to have hepatoprotective effects against hepatosteatosis and oxidative injury.\textsuperscript{27,28} thus this prescribed herbal drug might work to improve the hepatic inflammation.

The pattern of diseases evolves according to the change of environments, and the therapeutic strategy also should be changed. NAFLD and NASH constitute a new epidemic hepatic disorder which could be an optimal target the disease of TKM-based integrative treatment. This study reported the important clinical information and potential of TKM-therapies through a juvenile NASH case, thus will be helpful for the development of TKM-derived treatments for NAFLD and NASH.

Conflict of interest

The author declares no conflict of interest.

Acknowledgment

This study was supported by Daejeon University Research Grant (2016), Republic of Korea.

References

1. Zhu JZ, Zhou QY, Wang YM, Dai YN, Zhu J, Yu CH, et al. Prevalence of fatty liver disease and the economy in China: a systematic review. World J Gastroenterol 2015;21:5695–706.
2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.
3. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 981 million participants. Lancet 2011;377:557–67.
4. Younossi ZM, Henry L, Bush H, Mishra A. Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2018;22:1–10.
5. Puoti C, Elmo MG, Ceccarelli D, Ditrinco M. Liver steatosis: the new epidemic of the third millennium. Benign liver state or silent killer? Eur J Intern Med 2017;46:1–5.
6. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330–44.
7. Airaghi L, Rango M, Maira D, Barbieri V, Valenti L, Lombardi R, et al. Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. Atherosclerosis 2017;268:27–31.
8. Kim GA, Lee HC, Choe J, Kim MJ, Lee MJ, Chang HS, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol 2017. S0168-8278(17)32294-8.
9. Fan JG, Kim SJ, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862–73.
10. Anderson EL, Howe LD, Jones HE, Higgins JF, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLOS ONE 2015;10:e0140908.
11. Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. J Hepato 2017. S0168-8278(17)32294-8.
12. Marra F, Svegliati-Baroni G. Lipotoxicity and the gut–liver axis in NASH pathogenesis. J Hepato 2017. S0168-8278(17)32437-6.
C.-G. Son

13. Yao H, Qiao YJ, Zhao YL, Tao XF, Xu LN, Yin LH, et al. Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol 2016;22:6890–905.
14. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic fatty liver disease: a clinical update. J Clin Transl Hepatol 2017;5:384–93.
15. Kovalic AJ, Satapathy SK. The role of nonalcoholic fatty liver disease on cardiovascular manifestations and outcomes. Clin Liver Dis 2018;22:141–74.
16. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017;66:1138–53.
17. Son CG, Wei Z, Raghavendran HB, Wang JH, Janda E. Medicinal herbs and their active compounds for fatty liver diseases. Evid Based Complement Alternat Med 2017. Article ID 3612478.
18. VanWagner LB, Khan SS, Ning H, Siddique J, Lewis CE, Carr JJ, et al. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: the CARDIA cohort study. Liver Int 2017 [Epub ahead of print].
19. Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract 2016;2016:2862173.
20. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta 2015;1852:1765–78.
21. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis – new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013;10:627–36.
22. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology 2005;129:113–21.
23. Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 2012;32:30–8.
24. Lee HY, Lee WJ, Kim HW, Jang ES, Ahn YC, Ku BC, et al. A systematic review on sasang constitutional type-associated susceptibility to disorders in Korea. J Altern Complement Med 2016;22:950–6.
25. Golabi P, Bush H, Younossi ZM. Treatment strategies for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2017;21:739–53.
26. Romero-Gómez M, Zeber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017;67:829–46.
27. Park HJ, Han JM, Kim HG, Choi MK, Lee JS, Lee HW, et al. Chunggan extract (CGX), methionine-and choline-deficient (MCD) diet-induced hepatosteatosis and oxidative stress in C57BL/6 mice. Hum Exp Toxicol 2013;32:1258–69.
28. Kim HG, Wang JH, Han JM, Hwang SY, Lee DS, Son CG. Chunggan extract (CGX), a traditional Korean herbal medicine, exerts hepatoprotective effects in a rat model of chronic alcohol consumption. Phytother Res 2013;27:1854–62.